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Abstract
The G protein-coupled receptor (GPCR) family is among the most druggable families in the
human proteome. GPCRs are involved in most physiological processes, and our ability to
modulate their activity is a hallmark of modern pharmacology. The means by which the activity of
GPCRs can be modulated have been expanded by emerging data and concepts in pharmacology,
which has created new strategies for their control. These new approaches will lead to the
generation of more potent, selective, and efficient pharmaceutics, while reducing inappropriate
actions and adverse effects. Herein, we review and comment on some recent advances in chemical
and genetic approaches to the profiling of GPCR function, as well as the validation of orphan
GPCRs as potential therapeutic targets using engineered receptors.
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Introduction
An important hallmark of all living organisms is their ability to react and respond to their
environment. From unicellular to complex multicellular organisms, much of this sensory
capability is achieved through cell membrane embedded receptors that can transduce
extracellular signals into the intracellular milieu [1]. The nature of the extracellular signals is
highly divergent, and includes photons (light), a wide range of small molecules, as well as
larger molecules including peptides and proteins. Many of these stimuli exert their effects
through a distinct family of transmembrane receptors called G protein-coupled receptors
(GPCRs), which are characterized by having seven transmembrane helices linked by three
extracellular and three intracellular loops. In vitro and in vivo pharmacological studies have
consistently identified GPCRs as the most important class of druggable targets in the human
genome; this is supported by the fact that nearly 50% of prescribed therapeutics act through
modulation of GPCRs [2,3]. This high degree of druggability is derived both from the nature
of GPCR ligands as well as the intrinsic capability of GPCRs to be modulated by small
molecules at the canonical ligand-binding pocket (the orthosteric site) as well as additional
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allosteric sites [3]. Recent improvements in our capacity to generate high quality crystal
structures of GPCRs portend important advances in drug discovery [3,4]. However, as in all
drug development initiatives, drug discovery using these new insights is not guaranteed to
be clinically successful. Most approved drugs have a broad range of off-target activity,
which can account for the effectiveness of a medication through desirable effects, or can
result in deleterious side effects [5]. Indeed, “polypharmacology” is now well documented
[2,6]. In order to achieve the same clinical efficacy of known polypharmacological
compounds with new drugs, it will be important to understand more completely their
activities, especially with respect to identifying the specific target(s) essential for their
effectiveness. This, combined with a more complete understanding of off-target activities,
will allow for development of better therapeutics with lower side-effect profiles [7].
In order to achieve these goals, a wide range of pharmacological tools is required for
designing and screening of novel drugs, as well as to more fully understand the
pharmacology of already-prescribed drugs (e.g. see [5] and [6]). These tools will also lead to
a more complete understanding of the receptors involved in drug actions, as well as the
pairing of receptor activity with physiological and pathophysiological conditions. Herein,
we will review some recent advances in chemical and genetic approaches to the study of
GPCR function and activity.
From chemistry to pharmacology
Productive collaborations between chemists and biologists are now essential for successfully
interrogating GPCRs using chemical-based approaches. Through the use of already-known
drugs as templates, additional chemistry can help to identify specific essential determinants
within the molecule for the optimization of desired activities. Although selectivity and
efficacy have been the Holy Grail of pharmacologists for decades, it is now becoming
apparent that an additional concept may also become important in future drug design. This
concept, variously referred to as agonist trafficking, biased agonism, differential
engagement, protean agonism or functional selectivity [8,9] involves different signaling
outputs triggered by the same receptor, but using different modulators. Design of new drugs
that preferentially activate a single specific signal transduction pathway has the potential to
increase clinical effectiveness while decreasing undesirable activities or tolerance caused,
for example, by receptor desensitization [9].
An example of the potential for advancing our understanding of the functional selectivity of
drugs has resulted from the high resolution structure of a biased compound (ergotamine,
Erg) bound to the 5-HT2B serotonin receptor [10]. Erg has full agonist activity at the arrestin
recruitment pathway that is 100-fold more potent than its activity at Gq, while other
compounds show considerably less bias (Fig. 1). The crystal structure of Erg bound to the 5-
HT1B receptor, at which it acts as an unbiased full agonist, was also solved [11].
Comparison of these two crystal structures revealed specific molecular determinants
responsible for the biased activity at the 5-HT2B receptor [10,11]. These studies represent
the first description of the structural mechanism underlying the functional selectivity of a
GPCR ligand. It can be anticipated that similar studies will lead to the development of more
potent and selective GPCR ligands, with fewer side effects, even while taking into account
the minimal chemical properties required for bioavailability and appropriate in vivo
pharmacokinetics [4,6].
The goal of chemistry-based pharmacology is to find, develop, and optimize compounds for
particular desired outcomes, either as probes or drugs. With the maturation of concepts like
functional selectivity, chemistry-based pharmacology will be essential for the discovery and
refinement of drugs based on these newer concepts of drug action. In recent years, efforts
have been made to develop a more mathematical approach to quantify functional selectivity,
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for example by comparing two or more assays of drug potency or pathways of drug action
(review by Kenakin [9]). In its most usual implementation, we have compared canonical G
protein signaling (cAMP or Ca2+) with β-arrestin recruitment to study the biased activity of
a compound. However, since GPCR signaling, and the outcome of such signaling, may also
be dependent on many other pathways, measurement of biased activity at these additional
pathways will need to be considered for a full understanding of a drug's actions. Some
caution in interpretation is warranted, however, since it is quite conceivable that compounds
that exhibit bias in vitro might have considerably different behavior in vivo. It is also
possible that biased compounds use a variety of mechanisms to achieve their signaling bias.
In vitro pharmacology generates much information regarding selectivity, potency, and
efficacy—all of which are concepts essential to drug discovery. However, validation of the
therapeutic potential of new compounds requires additional studies in vivo, including
efficacy, toxicity and kinetic properties. In vivo studies can also provide novel means to
decipher GPCR signaling and to validate the potential therapeutic properties of a targeted
receptor. It is now feasible to do some of these studies even while lacking a known natural
ligand (e.g., for study of orphan receptors), or without potent small molecule agonists.
Advances such as these have initiated a “reverse pharmacology” approach, i.e., the study of
the therapeutic effect of a target before compound screening.
When chemistry meets genetics
Signals triggered by the activation of GPCRs are typically not simple “input-single output”
signals, but are rather an inter-regulated complex of signaling pathways that all lead to a
subset of possible physiological responses. This network of pathways, and their complex
effects, are dependent on both specific cellular micro-environments [12], and the distribution
of particular cell types within tissues [13]. It is well established that the same receptor can
elicit different responses in different environments, especially when considering the
differences between in vivo and in vitro conditions [14,15]. The requirement for
understanding of a receptor's function and regulation in the context of its normal
environment has accelerated the development of tools that allow this type of study.
Additionally, in response to the need to selectively activate only the targeted receptor, and
not others, as well as to study receptors for which no small molecule mediators are known, a
variety of engineered receptors have been developed [16,17].
The first generation of engineered receptors was dubbed `genetically engineered receptors'
and could respond to otherwise inert compounds while lacking responsiveness to all known
endogenous ligands [18]. The second generation was called RASSLs (Receptors Activated
Solely by Synthetic Ligands) and was based on the κ-opioid receptor [17,19]. The first two
generations of RASSLs had either low affinity towards their synthetic ligands [18], or had
residual affinity for endogenous ligands [19], or the novel ligands had unknown
pharmacokinetic properties limiting their use [18]. Although both technologies represented
major advances, due to their limitations we designed a third generation of engineered
receptors we called DREADDs (Designer Receptor Exclusively Activated by Designer
Drugs).
The first DREADD used the M3-ACh muscarinic receptor as its template. Mutation of only
two residues (Y149C/A239G) generated a receptor with essentially no affinity for the
endogenous acetylcholine ligand (ACh), but responding to clozapine-N-oxide (CNO) [20].
CNO is an inert metabolite of clozapine, an atypical antipsychotic drug with known
pharmacokinetic, pharmacodynamic and biodistribution properties [21]. From this initial
effort, a full panel of DREADDs was developed covering all three of the major G protein
signaling pathways – Gq (M3-DREADD), Gi (M4-DREADD) and Gs (Gs-DREADD), all
based on muscarinic receptors [20,22].
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To generate the Gs-DREADD, Guettier et al. [22] swapped the intracellular loops 2 and 3
(il2 and il3) of the original M3-DREADD receptor for those of the β1-adrenergic receptor,
which changed its G protein coupling from Gq to Gs. This chimeric receptor responds to,
and has affinity for, CNO similarly to its M3-DREADD parent, but signals through the Gs
pathway. This approach serves as a “proof of concept” that opens the possibility that, by
swapping the intracellular domains of a receptor of interest into a DREADD backbone,
receptors could be designed that respond to CNO while retaining their native cellular
signaling properties. This could be of particular interest when it is suspected that the target
receptor signals by novel pathways as yet not well studied or characterized. Alternative
domain-swapping strategies, for example by keeping the transmembrane portions of the
receptor of interest, might be useful for studies of dimerization (such as for the CXCR4
receptor [23]), as well as of interactions with membrane cholesterol, such as for the β2-
adrenergic receptor [24] and probably other GPCRs [25]. Since most GPCRs have increased
intrinsic activity when overexpressed, the choice of the muscarinic receptor template, which
has very low constitutive activity, was critical to detection of receptor activation by CNO.
This was particularly important since it was found that, in some cases, overexpression of the
previous generations of RASSLs induced a phenotype reflective of high constitutive activity
[17,26]. Since constitutive activity can be conferred by the membrane-proximal amino acids
at the end of il3 (near helix 6) [27], it should be possible by mutagenesis or domain
swapping to reduce constitutive activity of the targeted engineered receptor. Thus,
subsequent generations of RASSLs and DREADDs can be engineered to have all the
properties required for the successful study of receptor signaling and regulation in natural
cell and tissue environments.
Potential uses of DREADDs to profile GPCR function—By expressing DREADDs
(or chimeric DREADDs) in the same environment as a targeted receptor of interest, the
phenotype induced by CNO could then be used to measure adverse and/or beneficial effects
of activation of signaling in a particular cell type or tissue in mouse models of disease, and
thus could be used to validate the role and therapeutic potential of activation of receptors
naturally expressed in such cells or tissues (see ref [22] for example). Additionally, by
choosing different DREADDs, it would be possible to identify which signaling pathways
need to be activated to overcome a phenotype, or to cause a phenotype [22].
DREADDs may also be of use in the study of functional selectivity. For example, by
mutating the receptor in such a way that it will only stimulate a desired signaling pathway, it
will be possible to create a biased system in which its activation, in a desired environment,
will provide information about the potential of a biased compound to treat a disease, or to
reduce the adverse effects of a compound (Fig. 2). For example, Nakajima and Wess have
recently created a DREADD that only activates arrestin signaling pathways [28]. In a more
general sense, identification of the minimal properties of a drug that are required for a
beneficial outcome will better inform future drug development, as well as increase the
druggability of many GPCRs. Further study of compounds already available, and indeed
already prescribed, will identify the most beneficial signaling profiles, and will allow for the
modification of these existing molecules to direct their properties more precisely towards
their desired effect.
Conclusion
Our ability to design functionally selective compounds will allow us to fine-tune the
outcomes of GPCR signaling to increase drug potency and efficacy while decreasing
undesired, potentially harmful, side effects. These novel technologies have the potential to
help close the current gap that exists between in vitro and in vivo findings. The generation of
chimeric DREADDs using orphan GPCRs as partial template is likely to increase the
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number of GPCR druggable targets. The latter reverse pharmacology approaches, especially
when combined with more and better GPCR structural information, can be predicted to
accelerate discovery and development of new GPCR drugs for a variety of conditions.
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• Chemistry-based pharmacology helps find, develop and optimize new
compounds.
• Functionally selective drugs reveal novel strategies for GPCR remote control.
• Genetics pharmacology can validate the therapeutic potential of new
compounds.
• Engineered receptors provide a novel approach to decipher GPCR function in
vivo.
• Advances in chemical and genetic pharmacology will accelerate new drug
development.
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Figure 1. Structure-activity comparison of compounds having biased signaling properties at the
5-HT2B receptor
(A) Structure of different agonists having increasingly arrestin-biased activity (from left to
right) used in the studies published by Wacker et al. and Wang et al. [10,11]. The green box
highlights the common core shared by these agonists, including the endogenous ligand 5-HT
(serotonin). The efficacy at recruiting arrestin and activating G protein signaling (Gq for
5HT2B) were measured and the bias factor was quantified. (B) Concentration-response curve
of Ergotamine (Erg), which showed the most highly arrestin-biased activity at 5HT2B while
being unbiased at 5HT1B. The black curve (squares) shows Gq potency measured by
calcium release whereas the red curve illustrates arrestin recruitment. The arrow shows the
leftward shift in potency (increased potency) of Erg at arrestin recruitment compared to Gq
signaling. (C) Schematic representation of biased signaling induced by Erg at 5HT2B. The
crystal structure revealed a structural change at helices 3 and 7 induced by Erg at the 5HT2B
receptor generating an arrestin-polarized signaling.
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Figure 2. Schematic representation showing how DREADDs receptors could be used in a
chemical-genetic approach to study GPCR function as well as in drug discovery
The engineered receptor or chimeric receptor can be mutated and so that there is a loss-of-
function toward one or more specific pathways. This biased DREADDs is then incorporated
into viral particles and injected into mice, or used to generate recombinant or knockin-mice;
in both scenarios, expression of the receptor driven by a tissue- or cell-specific promoter, or
the natural promoter for the targeted GPCR. The use of a natural promoter allows a more
physiological expression level and spatiotemporal regulation. Once the receptor is
expressed, the mice are injected with the inert agonist (e.g CNO) and specific outcomes and
phenotypes are analyzed. Specific compound libraries (i.e. compounds known to interact
with a targeted receptor) or random libraries are used to screen for drugs stimulating the
signaling pathway previously identified by the DREADD that may have potentially
clinically useful properties.
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